Clinical Trial 46649

Pearland, TX 77584


You have been asked to participate in this study because you have Active Ulcerative Colitis (UC). The study drug is a novel (first-in-class small molecule) oral study treatment for UC. NX-13 activates the Nod-like receptor X1; (NLRX1), which may improve the condition of the bowel.

Qualified Participants Must:

• Have diagnosis of UC for 90 days or more prior to screening.
• Other criteria will apply. Details will be provided.

Qualified Participants May Receive:

You will receive up to $100 following each completed study visit.

Clinical trials are medical research studies designed to test the safety and/or effectiveness of new investigational drugs, devices, or treatments in humans. These studies are conducted worldwide for a range of conditions and illnesses. Learn more about clinical research and participating in a study at About Clinical Trials.